Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 791 across all filing types
Latest filing 2023-11-06 Capital/Financing Update
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment
Capital/Financing Update Classification · 98% confidence The document is explicitly titled as a "PRESS RELEASE" announcing the "AVAILABILITY OF A PROSPECTUS IN CONNECTION WITH CAPITAL INCREASES RAISING TOTAL GROSS PROCEEDS OF APPROXIMATELY $50M". It details two share capital increases and the exercise of an over-allotment option, which are financing activities. The text mentions the approval of a listing prospectus by the AMF and lists the components of this prospectus (Universal Registration Document, amendments, securities note). Since the document is an announcement about the availability of financing documents (prospectus/securities note) related to raising capital, it strongly aligns with the definition of a Capital/Financing Update (CAP). While it mentions the availability of a prospectus, the core subject is the capital raise itself, making CAP more specific than RPA or RNS, although it functions as a regulatory announcement.
2023-11-06 English
NANOBIOTIX annonce le lancement d’une offre globale et d’un placement prive concomitant ainsi que la renonciation par la BEI de l’engagement de tresorerie minimum dont elle beneficie
Capital/Financing Update Classification · 99% confidence The document is a press release dated November 1, 2023, announcing the launch of a 'global offering' and a 'concomitant private placement' of American Depositary Shares (ADSs) and Ordinary Shares. It details the underwriters, the intention to use proceeds for clinical trials and R&D, and mentions the filing of a preliminary prospectus supplement on Form F-3 with the SEC. This clearly describes a corporate action related to raising capital through the issuance of new securities. This aligns directly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV).
2023-11-01 French
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant
Capital/Financing Update Classification · 98% confidence The document is a press release announcing the launch of a 'global follow-on offering' and a 'concurrent private placement' involving the issuance of American Depositary Shares (ADSs) and Ordinary Shares. It details the underwriters, the use of proceeds, and references SEC filings (Form F-3, Preliminary Prospectus Supplement) and French regulatory filings (AMF). This activity directly relates to raising capital and changing the company's share structure. Based on the definitions, 'Capital/Financing Update' (CAP) is the most appropriate classification for an announcement detailing a securities offering and capital raise, rather than a general regulatory filing (RNS) or a share issue announcement (SHA), as CAP specifically covers fundraising activities.
2023-11-01 English
NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023
Earnings Release Classification · 98% confidence The document is explicitly titled "# *PRESS RELEASE*" and announces updated preliminary results from clinical trials (Phase 1 Pancreatic Cancer Trial and Phase 1 Head and Neck Cancer Trial) presented at ESMO 2023. It contains key financial/operational highlights, forward-looking statements, and contact information typical of a company press release regarding scientific updates. This format strongly suggests an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release announcing scientific/clinical data updates rather than strictly quarterly financial performance highlights (ER), and it is a formal announcement that doesn't fit other specific categories like 10-K, AR, or IP, the most appropriate classification is the general Regulatory Filing category, RNS, as it serves as a broad regulatory disclosure mechanism for material, non-financial news. However, given the content is focused on clinical trial results and efficacy data, which is often disseminated via an Investor Presentation (IP) or sometimes an Earnings Release (ER) if tied to a reporting period, I must re-evaluate. Since it is a 'Press Release' announcing data, and not a formal presentation deck (IP) or a summary of quarterly financials (ER), RNS remains the best fit for a general, material announcement that isn't a core financial report. If the document were a summary of quarterly earnings, ER would be chosen. Since it is a scientific update press release, RNS is the fallback for material announcements. FY 2023
2023-10-23 English
ESMO 2023 : NANOBIOTIX annonce une mise a jour des résultats préliminaires d’une étude de phase 1 dans le cancer du pancréas et une nouvelle analyse exploratoire de l’étude 102 dans les cancers de la
Earnings Release Classification · 92% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and is dated October 23, 2023. It announces updated preliminary results from clinical studies (Phase 1 in pancreatic cancer and Study 102 in head and neck cancer) presented at the ESMO 2023 congress. This type of document, which summarizes key scientific or clinical findings and is issued to the public and investors, fits the description of an Earnings Release (ER) if it were financial results, or more generally, a communication of important company news. Since the content is focused on clinical trial data updates and scientific presentations rather than formal financial performance (which would suggest ER or IR), and it is a press release format, it is best classified as an announcement of important company information. Given the options, this is a general corporate announcement detailing scientific progress, which often accompanies or precedes a formal report. However, it is not a full report (10-K, IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV. It is a high-level summary of data presented at a conference. In the context of financial filings, press releases announcing clinical data updates are often categorized under general regulatory announcements or investor relations material. Since it is a detailed announcement of results presented at a conference, it is most closely aligned with an Investor Presentation (IP) or a general Regulatory Filing (RNS) if no better fit exists. Given the detailed nature of the data presented (mOS, PFS, specific study numbers), it functions as an investor update. However, since it is a press release announcing data presented elsewhere (ESMO), and not the presentation itself (IP), the most appropriate general category for significant, non-standard regulatory news is RNS, or if we interpret the content as providing key investor information, IP. Since it is a press release summarizing conference data, and not the presentation slides themselves, RNS is the safest fallback for significant, non-standard corporate news. If the document were purely financial results highlights, ER would apply. Since it is clinical/scientific highlights, RNS is the best fit among the provided options for a general, important announcement that isn't a formal report or a specific transaction notice. FY 2023
2023-10-23 French
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and its subject is "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly cites French commercial code (L.233-8 II du Code de commerce) and AMF regulations (223-16 du Règlement Général de l'Autorité des Marchés Financiers). This type of regular disclosure regarding the total number of shares and voting rights is a specific regulatory requirement in France, often related to major shareholding notifications or capital structure transparency. While it relates to share capital, it is a mandatory monthly disclosure rather than a transaction announcement (POS) or a general capital change announcement (SHA). It is a specific regulatory filing concerning share structure transparency. Given the options, this fits best under the general regulatory filing category (RNS) or potentially a specific notification related to share capital changes, but since it's a recurring, mandated disclosure about the total share count, RNS (Regulatory Filings) is the most appropriate general bucket for non-standard, mandatory regulatory updates that aren't 10-K, ER, or IR. However, looking closely at the definitions, 'Major Shareholding Notification' (MRQ) deals with crossing thresholds, and this document provides the baseline count monthly. Since it is a mandatory regulatory disclosure about the capital structure, RNS is the safest fallback, but let's re-evaluate if any other code fits better. None of the other codes (like DIV, CAP, SHA) specifically cover this mandatory monthly voting rights disclosure. Therefore, RNS (Regulatory Filings) is the best fit as a general regulatory announcement.
2023-10-11 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.